Sila Realty Trust (SILA) Review 2026: The Full Cycle Is Over — Blue Owl Took It Private at $30.38 a Share, and the Original $10 Investor Ended Down 24%
Quick Answer
Sila Realty Trust, Inc. (formerly NYSE: SILA, SEC CIK 1567925) scores 3.1 out of 5 in this forensic SEC-primary-source review. Update, August 23, 2026 — this story now has an ending. SILA no longer trades. On July 1, 2026 it was acquired in an all-cash take-private by Blue Owl Real Estate Net Lease Trust (ORENT), and every outstanding share was "cancelled, retired and automatically converted into the right to receive an amount in cash equal to $30.38 per share" per the company's own Form 8-K. The NYSE delisting notice (Form 25-NSE) was filed the same day and the deregistration (Form 15-12G) on July 13, 2026. That closes the full cycle, and the final number is better than the one this page carried in June: against the $40.00 split-adjusted cost basis of an original $10.00 non-traded share, $30.38 is a 24.05% capital loss before distributions — not the roughly 36% implied by the mid-2026 trading price — and it is 1.5% above the board's last stated NAV of $29.92. Blue Owl paid approximately $2,452,674,000 in total for the company including transaction costs, funded from its credit facility, per ORENT's Form 10-Q. The original review, written while SILA still traded, follows unchanged except where the facts moved. It belongs in our "listed non-traded REIT" tier because it started as one: SILA was originally Carter Validus Mission Critical REIT II, Inc., a non-traded REIT sponsored by Carter Validus that raised about $1.4 billion from retail investors at $10.00 a share between 2014 and 2018. It internalized management and renamed itself Sila in September 2020, then direct-listed on the NYSE on June 13, 2024 after a 1-for-4 reverse stock split. Here is the number that matters: the board's last estimated value was $7.48 a share pre-split, or $29.92 split-adjusted — and the public market disagreed immediately. SILA opened at $19.00 and closed its first day at $22.70, a roughly 24% discount to the board's NAV at the close (about 36% at the open). Measured against the original $10 offering price — which becomes a $40.00 cost basis after the 1-for-4 split — shares around $25.50 in mid-2026 leave an original Carter Validus investor down roughly 36% on principal before distributions. The credit to SILA: present-day it is a clean, conservatively financed, internally managed pure-play healthcare net-lease REIT. It sold its 29-property data-center portfolio to Mapletree for about $1.32 billion in 2021 (good timing), runs 137 properties at 98.7% leased with a roughly 10-year weighted-average lease term, carries low leverage (about 3.5x net debt to EBITDAre), and pays a well-covered roughly 6.3% dividend (Q1 2026 AFFO of $0.61 a share against a $0.40 quarterly payout, a 67% payout ratio). The drags: a single tenant, PAM Health, is about 16% of revenue, a major tenant (GenesisCare) went bankrupt in 2023, and the share-repurchase program was frozen for about four years (2020-2024) before the listing gave holders any exit. There is no affiliate program; CrowdfundedWealth earns nothing on this review.
CSV · 7 rows
The data table in this article, as CSV
The 7-row table from this article as CSV: Reference point, Per-share value (split-adjusted), Implied verdict. Sources are listed in the article.
A meaningful gap. SILA's board carried a $29.92 split-adjusted NAV ($7.48 pre-split) into the June 2024 direct listing; the market opened it at $19.00 (about a 36% discount) and closed day one at $22.70 (about 24%). The company's own simultaneous Dutch-auction tender capped at $22.60-$24.00 — management itself priced a buyback roughly 22% below its stated NAV
Poor. After the 1-for-4 reverse split, an original $10 non-traded share carries a $40 cost basis against a roughly $25.50 mid-2026 price — about a 36% capital loss before distributions. A decade of distributions (cut during COVID) plus a 2021 special distribution from the data-center sale cushioned but did not reverse it
Well-covered today. The $0.40 quarterly dividend ($1.60 annualized, about 6.3% yield) is backed by Q1 2026 AFFO of $0.61 a share — a 67% payout ratio with real headroom. But the non-traded-era distribution was cut during COVID, so the track record is not spotless
137 healthcare net-lease properties, about 5.3 million square feet, 98.7% leased, roughly 10-year weighted-average lease term. Defensive outpatient/inpatient healthcare real estate. The catch: tenant concentration — PAM Health is about 16% of rental revenue, and the 2023 GenesisCare bankruptcy forced re-tenanting of 17 properties
The strongest in the tier. About 3.5x net debt to EBITDAre, roughly 33% net debt to enterprise value, about 76% fixed-rate, a 4.7% weighted-average rate, and about $466 million of liquidity with no near-term maturity wall. Genuinely conservative
Carter Validus ran two non-traded REITs (MC REIT I and II), both sold at $10 and both leaving original investors below par. SILA internalized in 2020, paying about $40 million to buy out the advisor — removing the external-fee conflict before listing — but a four-year SRP freeze and opportunistic sub-NAV mini-tenders defined the non-traded experience
Internally managed since September 2020 under CEO Michael Seton. The clean data-center exit to Mapletree near the cycle top (about $1.32 billion, 2021) was a genuinely good capital-allocation call, and the post-listing balance sheet is disciplined
Publicly traded on the NYSE; no retail affiliate or referral program. Generic informational link only; we earn nothing
Why this review exists: a healthier vehicle, an honest-but-painful listing
Most of our "listed non-traded REIT" tier is a study in how wrong a board-set NAV can be — Peakstone listed about 83% below its stated value, SmartStop about 48% below, New York City REIT about 64% below. Sila sits in the middle of that ladder, and it is a more nuanced case than the wrecks: the present-day company is genuinely good, but the listing still repriced the board's NAV down by roughly a quarter, and original investors still lost about a third of their capital.
SILA was born as Carter Validus Mission Critical REIT II, Inc., a non-traded REIT raised between 2014 and 2018 that sold about $1.4 billion of stock to retail investors at $10.00 a share to buy "mission critical" net-leased real estate — data centers and healthcare. It internalized and renamed itself Sila Realty Trust in September 2020, then direct-listed on the NYSE in June 2024. This review is built from primary EDGAR filings under CIK 1567925 — the estimated-value 8-Ks, the internalization filing, the listing materials, and the FY2025 10-K and Q1 2026 results.
Checklist · PDF · 1 page
The 8 red flags we check in every SEC filing
Going-concern language, cash-burn, suspended redemptions, appraisal-NAV gaps. Comes with the watchlist: the next platform showing these signs, before it makes the news.
The listing math: about a 24% haircut at the close
Carter Validus carried a last estimated value of $7.48 a share (approved December 2023, valued as of October 31, 2023). After the 1-for-4 reverse split in May 2024, that becomes $29.92 split-adjusted. Then the market spoke.
| Reference point | Per-share value (split-adjusted) | Implied verdict |
|---|---|---|
| Original non-traded offering price (2014-2018) | $40.00 | What retail investors paid, $10 pre-split |
| Last board NAV before listing (Oct 31, 2023) | $29.92 | Board's own value, already about 25% below cost |
| First-day open (June 13, 2024) | $19.00 | About a 36% discount to the board NAV |
| First-day close (June 13, 2024) | $22.70 | About a 24% discount to the board NAV |
| Company Dutch-auction tender range (same day) | $22.60-$24.00 | Management priced a buyback about 22% below NAV |
| Mid-2026 trading price | about $25.50 | About a 36% loss on the original $40 basis |
| Blue Owl take-private, July 1, 2026 | $30.38 cash | The final answer: 24.05% loss on the $40 basis, and 1.5% ABOVE the board's last NAV |
Two things stand out. First, the board's own NAV was already about 25% below the $40 cost basis before the market ever traded a share — the non-traded value had eroded over the decade. Second, the market then discounted even that reduced NAV by roughly a quarter on day one, and the company's simultaneous self-tender effectively ratified the gap by capping its buyback below the stated NAV. On the NAV-discount ladder, Sila's roughly 24-36% gap sits between net-lease quality (shallow) and office (deep) — consistent with healthcare real estate that had taken real tenant-credit damage.
How original Carter Validus investors actually did
The honest summary is now final rather than provisional: an original $10 buyer exited at $30.38 in cash on July 1, 2026, down 24.05% on principal, partly cushioned by distributions. When this page was first written in June the reference point was the roughly $25.50 market price, which implied a ~36% loss; the take-private premium closed about twelve points of that gap, and we have corrected the figure upward accordingly. Note what that means: the buyer of last resort paid slightly more than the board's own last stated NAV — $30.38 against $29.92 — which is a better outcome than the public market ever offered these shareholders in two years of trading. Walk the numbers. The estimated value fell from $10.00 at the offering to $8.65 (2019), then $8.69 (2020), then $8.13 (March 2023), then $7.48 (October 2023) — it never recovered to par. The distribution was cut during COVID (2020) from about $0.62 annualized toward roughly $0.50. A one-time special distribution accompanied the 2021 data-center sale, returning some capital. And the share-repurchase program was partially suspended in April 2020 and stayed restricted until the 2024 listing — so for about four years, a holder who needed cash either sold to a lowball mini-tender (Comrit bid $6.01 a share in 2020) or waited.
Add it up and the realistic total return for an original holder over roughly a decade is modestly negative to around break-even, depending on entry year and reinvestment — a poor result versus listed healthcare-REIT peers over the same span, and a clean illustration of non-traded-REIT cost-and-illiquidity drag.
What the business was, at the moment it stopped being public
Strip away the non-traded history and present-day SILA is, frankly, one of the better-run vehicles in this tier. The 2021 decision to sell the entire 29-property data-center portfolio to Mapletree for about $1.32 billion — near the top of the data-center valuation cycle — was a sharp capital-allocation call that left the REIT focused and well-capitalized. Today it is a pure-play healthcare net-lease REIT: 137 properties, about 5.3 million square feet, 98.7% leased, roughly a 10-year weighted-average lease term, financed conservatively at about 3.5x net debt to EBITDAre (the lowest leverage in this tier), roughly 76% fixed-rate, with about $466 million of liquidity and no near-term maturity wall. The $1.60 annualized dividend (about 6.3% yield) is well covered by Q1 2026 AFFO of $0.61 a share — a 67% payout ratio with genuine headroom.
The honest negatives are concentration and tenant credit, not the balance sheet. PAM Health (Post Acute Medical) is about 16% of rental revenue — single-tenant risk that matters. And the recent history is not spotless: GenesisCare USA filed Chapter 11 in June 2023, affecting 17 Sila radiation-oncology properties, which had to be re-tenanted. Those qualities are precisely why it was bought. A pure-play healthcare net-lease portfolio at 98.7% leased on a ten-year weighted-average lease term, levered at about 3.5x, trading below its own board's NAV, is exactly the asset a large private buyer wants and exactly the situation a public market discount creates. You can no longer buy it at any price — the shares were cancelled for cash on July 1, 2026 and the 141 properties now sit inside Blue Owl Real Estate Net Lease Trust, an accredited-only private REIT. For the original $10 investor it remained an expensive lesson, just a less expensive one than the tape suggested in June.
How it sits in the cluster
Sila lands at 3.1, alongside SmartStop (3.1) and just above Modiv (3.0) and InvenTrust (3.0). Its conservative balance sheet and well-covered yield are the best in the tier, which lifts it above the office wrecks of Peakstone (2.4) and New York City REIT (1.7) and above GNL (2.7). What keeps it from scoring higher is the original-investor record: a roughly 24-36% day-one discount, a roughly 36% principal loss, a four-year redemption freeze, and real tenant concentration. Its contribution to the NAV-discount ladder is the reminder that a healthy operating REIT and a fair deal for the original retail buyer are two different questions. For the broader lesson on how these vehicles trap capital before any listing, see our real estate crowdfunding liquidity analysis, and for accredited-investor healthcare and net-lease alternatives, our best real estate crowdfunding for accredited investors guide.
ProsCons
Pros
- The most conservative balance sheet in the tier — about 3.5x net debt to EBITDAre, roughly 76% fixed-rate, about $466 million of liquidity, and no near-term maturity wall
- A well-covered roughly 6.3% dividend — Q1 2026 AFFO of $0.61 a share against a $0.40 quarterly payout is a 67% payout ratio with real headroom
- A genuinely good capital-allocation call — selling the entire data-center portfolio to Mapletree for about $1.32 billion in 2021, near the cycle top, then refocusing on defensive healthcare net lease
- Internally managed since 2020 — the external-advisor fee conflict was removed (for about $40 million) four years before the listing, and the portfolio is 98.7% leased with a roughly 10-year lease term
Cons
- A roughly 36% capital loss for original investors — a $40 split-adjusted cost basis against a roughly $25.50 price, even after the data-center windfall
- The market repriced the board NAV down about 24% at the first-day close (about 36% at the open), and management's own tender capped a buyback below the stated NAV
- Tenant concentration — PAM Health is about 16% of rental revenue, and the 2023 GenesisCare bankruptcy forced re-tenanting of 17 properties
- A roughly four-year redemption freeze — the share-repurchase program was suspended from April 2020 until the 2024 listing, locking in non-traded holders
- No retail affiliate program — publicly traded; we take nothing from it
FAQ
Frequently Asked Questions
Keep reading.
- 0119 min read
Fortress Net Lease REIT (FNLR) Review 2026: Without Its Appraisal Gains, NAV per Unit Has Been Flat Since 2024
Fortress Net Lease REIT (SEC CIK 1966394), the privately placed net-lease NAV REIT sold to accredited investors, read from its 10-Ks, 10-Qs and monthly 8-Ks: NAV of $2.03 billion at June 30, 2026, of which $175.2 million is the adviser's unrealized appreciation; 96% cash-flow coverage that depends on fees paid in units; 26.4% of 2025 purchases bought from Fortress affiliates; and $1.36 billion of debt with an October 16, 2026 maturity date.
- 0217 min read
GTJ REIT Review 2026: Three Prices for One Share — $29.10 NAV, $26.19 to Redeem, $22.35 for the Equity Plan
GTJ REIT (SEC CIK 1368757), the self-managed industrial REIT that grew out of three New York bus companies, values its shares at $29.10 (the bottom of its appraiser's range), redeems about $2 million a year at $26.19 and fills that cap by June, and uses a third figure, $22.35, for its own equity plan. Its NAV has more than doubled since 2016 and its dividend is covered. What the filings show a holder with no other exit.
- 0317 min read
Highlands REIT Review 2026: Ten Years, No Distributions, a $0.29 NAV and One Detention-Center Lease Worth 38% of Its Rent
Highlands REIT (SEC CIK 1661458) was spun out of InvenTrust in 2016 at $0.36 a share. Ten years of filings later: estimated value $0.29, no distribution in any year, one 2023 buyback at $0.14, about $127.5 million of G&A, four annual meetings without a quorum, and a Colorado prison that GEO left in 2020, was written off, and has just been leased back to GEO at rent equal to 38% of the whole portfolio's. What a holder deciding on the $0.20 tender should know.